2026 Update of the decision-making algorithm on selecting transfusion-dependent β-thalassemic patients for gene therapy approaches: joint consensus report on behalf of EHA-specialized working group and EBMT hemoglobinopathies working party Group Haemoglobinopathies Working Party (HWP) Other society 1st listed author Lucia de Franceschi Journal Bone Marrow Transplant.
2026 Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study Group Severe Aplastic Anaemia Working Party (SAAWP) 1st listed author Antonio M Risitano Journal Am J Hematol.
2026 Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation Group Acute Leukemia Working Party (ALWP) 1st listed author Enrico Maffini Journal Bone Marrow Transplant.
2026 HLA-B*15:01 and HLA-DRB1*07:01 as novel markers of acute GVHD in pediatric HSCT Group Paediatric Diseases Working Party (PDWP) 1st listed author Covida Mootoosamy Journal Bone Marrow Transplant.
2026 Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Bone Marrow Transplant.
2026 Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee Group Practice Harmonisation and Guidelines Committee 1st listed author Peter Dreger Journal Bone Marrow Transplant.
2026 A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia Group Acute Leukemia Working Party (ALWP) 1st listed author Alexandros Spyridonidis Journal Bone Marrow Transplant.
2026 Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Ryszard Swoboda Journal Bone Marrow Transplant.
2026 The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL) Group Lymphoma Working Party (LWP) 1st listed author Anna Ossami Saidy Journal Bone Marrow Transplant.
2026 Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author A Kanellopoulos Journal Bone Marrow Transplant.
2026 Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study Group Lymphoma Working Party (LWP) 1st listed author Simon Renders Journal Leukemia.
2026 Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT Group Cellular Therapy & Immunobiology Working Party (CTIWP) 1st listed author Guillaume Dachy Journal Bone Marrow Transplant.